Eloralintide
Also known as LY3841136
Eloralintide is an investigational long-acting peptide that preferentially activates amylin receptors over the calcitonin receptor. Researchers study it to test whether amylin receptor selectivity affects weight reduction and tolerability in obesity.
Clinical-stage research
Size
2 options- Catalog no.
- ERA5
- Specification
- 5mg*10vials
- Per kit
- 10 vials
For laboratory research use only. Not for human or animal consumption. Buyers must be 21 or older.
Overview
Eloralintide was developed by Eli Lilly under the code LY3841136. It is a long-acting amylin receptor agonist designed to favor amylin receptors, particularly the AMY1 subtype, over the calcitonin receptor. This contrasts with cagrilintide, which activates both. In lean rats it caused less conditioned taste avoidance, a marker of aversion, than cagrilintide. It has completed phase 1 and phase 2 trials in obesity. Lilly announced plans for phase 3 monotherapy studies and is also studying it with incretin therapy. It is not an approved drug.
Class: Selective amylin receptor agonist
Mechanism of action
How the compound acts, as described in the literature.
In cell assays it activated the human AMY1 receptor about 12-fold more potently than the calcitonin receptor and about 11-fold more potently than AMY3.
Amylin receptors in hindbrain satiety regions reduce food intake when activated. In diet-induced obese rats, eloralintide lowered food intake and body weight, mainly through fat mass loss.
Selectivity for amylin over calcitonin receptors is proposed as a way to improve tolerability, based on less taste avoidance than cagrilintide in rats.
Pharmacokinetic studies in rats, monkeys, and humans showed a long half-life, and exposure increased in proportion to dose in phase 1.
Published research
Selected studies, each linked to its PubMed record. Summaries describe what the studies reported.
2025
Phase 2 RCT
PMID 41207310Eloralintide, a selective amylin receptor agonist for the treatment of obesity: a 48-week phase 2, multicentre, double-blind, randomised, placebo-controlled trial.
Billings LK, et al. · Lancet
263 adults with obesity or overweight without type 2 diabetes were randomized to several dose regimens or placebo. At 48 weeks, mean body-weight change ranged from about -9% to -20% versus -0.4% with placebo.
2025
Discovery and phase 1 study
PMID 41109426Eloralintide (LY3841136), a novel amylin receptor agonist for the treatment of obesity: From discovery to clinical proof of concept.
Briere DA, et al. · Mol Metab
Reported AMY1-preferring activity in vitro, lower food intake and fat mass in obese rats, less taste avoidance than cagrilintide, and dose-related weight reduction after a single dose in 48 healthy participants.
2026
Phase 1 RCT
PMID 41559929Eloralintide, a selective, long-acting amylin receptor agonist for treatment of obesity: Phase 1 proof of concept.
Bhattachar S, et al. · Diabetes Obes Metab
A 12-week multiple ascending dose study in 100 adults with overweight or obesity reported dose-proportional exposure and mean weight reductions of 2.6% to 11.3%; decreased appetite was the most common adverse event.
Evidence & safety
What the research does not show, and the adverse events and regulatory status it reports.
Eloralintide is investigational, and the largest published trial enrolled 263 participants for 48 weeks; no phase 3 results have been published. In that trial, nausea occurred in up to 64% of a dose group versus 14% with placebo, and fatigue in up to 43% versus 12%. The tolerability advantage suggested by rat studies has not been tested head to head in people.
Specifications
All sizes, exactly as catalogued.
| Catalog no. | Product | Specification | Vials per kit |
|---|---|---|---|
| ERA5 | Eloralintide | 5mg*10vials | 10 |
| ERA10 | Eloralintide | 10mg*10vials | 10 |
For laboratory research use only. Not for human or animal consumption. Not intended to diagnose, treat, cure or prevent any disease. Research summaries are provided for educational purposes and do not describe this product’s use.